GENERIC DRUG NAME
(Brand Name – Company)

The information contained within this plain language version of the CEDAC Final Recommendation and Reasons for Recommendation is based on the information found within the corresponding technical version of the CEDAC Final Recommendation and Reasons for Recommendation for this drug.

Drug:
The brief, plain language description of the drug and the Health Canada indication.

Dose:
Available dosages, usual treatment dose and schedule.

CEDAC Recommendation:
The Canadian Expert Drug Advisory Committee (CEDAC) recommends that … (recommendation quoted).

Reasons for the Recommendation:
1. Plain language versions of the CEDAC Reasons for Recommendation.

Summary of Committee Considerations:
- A brief, plain language summary of relevant information found within the “Summary of Committee Considerations” and “Of Note” sections.

Background:
CEDAC is a CADTH committee consisting of various experts, as well as public members. CEDAC makes recommendations on whether or not drugs should be included in the list of medications that are covered by the participating publicly funded drug plans. However, the final decision rests with the individual drug plans themselves.

The Committee bases its recommendations on the submission from the manufacturer and on the best available medical and economic evidence compiled and reviewed by the Common Drug Review at CADTH. Using this information, CEDAC considers the effectiveness, safety, and cost-effectiveness compared to an existing drug(s) or therapies and determines if the drug under review offers good value for money for the participating public drug plans.

Common Drug Review
CEDAC Meeting – Month Day, Year